Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.
Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3, multicenter, open-label randomized trial compared tambotatug pelitecan with topotecan in patients whose small-cell lung cancer had progressed after first-line platinum-based therapy. At a prespecified interim analysis of 451 randomized patients, median overall survival was 13.3 months with tambotatug pelitecan and 9.4 months with topotecan; the stratified hazard ratio for death was 0.46 (95% CI, 0.35 to 0.62; P<0.001). Tambotatug pelitecan also improved progression-free survival and objective response, with fewer grade 3 or higher adverse events.
Key findings
- Median overall survival was 13.3 months with tambotatug pelitecan versus 9.4 months with topotecan (hazard ratio for death, 0.46; 95% CI, 0.35 to 0.62; P<0.001).
- Median progression-free survival was 7.4 months versus 2.8 months (hazard ratio, 0.29; 95% CI, 0.23 to 0.37; P<0.001).
- Confirmed objective response occurred in 59.1% versus 9.7% of patients (P<0.001).
- Grade 3 or higher adverse events occurred in 55.4% with tambotatug pelitecan and 77.9% with topotecan.
Why it matters
Relapsed small-cell lung cancer after platinum-based therapy is the setting studied, and the randomized comparison found improvements across survival, disease control, and response outcomes. The lower incidence of severe adverse events also informs the benefit-harm profile relative to topotecan. These results provide clinically relevant comparative evidence for this treatment setting, while reflecting an interim analysis.
What to keep in mind
The reported results are from a prespecified interim analysis; the abstract does not provide further follow-up details.